dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
  • Home
  • UnternehmenAC Immune SA

31.03.2021: AC Immune SA

AC Immune Hosts Investor Webinar Highlighting the Power of its MorphomerTM Platform to Enable Precision Medicine for Neurodegenerative Disease

Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss the unique benefits of the Company’s innovative MorphomerTM technology platform, which generates first-in-class therapeutic and diagnostic candidates to power AC Immune’s precision medicine approach for neurodegenerative diseases. The live webinar begins at 10am ET and can be accessed here.

Den gesamten Artikel lesen Sie bitte hier

News 2021

26.03.2021: AC Immune SA

AC Immune to Host Webinar Highlighting its Innovative MorphomerTM Technology Platform and Pipeline

Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases

Webinar will take place on Wednesday, March 31, 2021 at 10:00 AM ET

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a corporate update webinar on Wednesday, March 31st at 10:00 AM ET until 11:30 AM ET.

Den gesamten Artikel lesen Sie bitte hier

News 2021

23.03.2021: AC Immune SA

AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook

  • Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3
  • Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b safety and immunogenicity results in Down syndrome; further interim results expected in Q2 for Phase 2 in Alzheimer’s disease
  • Morphomer™ Tau aggregation inhibitor achieves target brain exposure in Phase 1; program advancing in NeuroOrphan indications and Alzheimer’s disease
  • First-in-class alpha-synuclein PET diagnostic to report clinical results in Q3 2021
  • Advancing multiple candidates targeting the NLRP3 inflammasome athway for CNS and non-CNS indications
  • Ongoing strong financial position of CHF 225.9 million in cash ensures the Company is fully financed through Q1 2024, excluding potential incoming milestones

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020. The Company also provided an overview of its execution strategy and anticipated clinical and preclinical milestones for 2021, as well as the strong progress being made across its broad portfolio of therapeutic and diagnostic product candidates.

Den gesamten Artikel lesen Sie bitte hier

News 2021

16.03.2021: AC Immune SA

AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium

Reported new data in non-human primates for optimized vaccine formulation which shows strong response against key pathological Abeta species, including oligomeric and pyroglutamate Abeta

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and prevent the progression of Down syndrome (DS)-related Alzheimer’s disease (AD). Topline results reported today by AC Immune’s Chief Scientific Officer, Dr. Marie Kosco-Vilbois, at a global DS symposium co-sponsored by AC Immune, showed that ACI-24 demonstrated encouraging immunogenicity and safety in Phase 1b clinical testing in people with DS. The Company also disclosed new non-human primate data for an optimized formulation of the vaccine, which shows broad potential for the treatment and prevention of Abeta-driven diseases based on its superior efficacy in non-human primates.

Den gesamten Artikel lesen Sie bitte hier

News 2021

09.03.2021: AC Immune SA

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

Four presentations at AD/PDTM 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43

First biologically active small molecule inhibitors of intracellular alpha-synuclein aggregation advancing toward in vivo proof-of-concept studies

Anti-TDP-43 therapeutic antibody candidates demonstrate dual mechanism of action against pathological TDP-43 in vivo

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today outlined new preclinical data that will be presented at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM), taking place virtually from March 9–14, 2021. Data from the Company’s wholly owned, first-in-class therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP- 43) are described during four oral and e-poster presentations. Together the presentations further illustrate the synergy between AC Immune’s SupraAntigenTM and MorphomerTM technology
platforms to deliver a precision medicine approach to treating neurodegenerative diseases (NDD).

Den gesamten Artikel lesen Sie bitte hier

News 2021

24.02.2021: AC Immune SA

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that four new data presentations will be delivered at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM), taking place virtually from March 9–14, 2021. The presentations will highlight preclinical results from the Company’s wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.

Den gesamten Artikel lesen Sie bitte hier

News 2021

17.02.2021: AC Immune SA

AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 22–26, 2021.

Den gesamten Artikel lesen Sie bitte hier

News 2021

11.02.2021: AC Immune SA

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease

ACI-35.030 was safe and well tolerated with no safety concerns observed. Results support plans to further develop the Alzheimer’s vaccine into Phase 2/3

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. No clinically relevant adverse events were observed. AC Immune and strategic partner Janssen Pharmaceuticals, Inc., believe these interim findings from the first two dosing groups support plans to advance the development of ACI-35.030 for the treatment of AD.

Den gesamten Artikel lesen Sie bitte hier
News 2021

08.02.2021: AC Immune SA

AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its novel diagnostic agent for Parkinson’s disease (PD). ACI-12589 is a next-generation positron emission tomography (PET) imaging tracer that has shown significant potential to reliably detect and map deposits of pathological alpha-synuclein protein in the brain, which is the major hallmark of PD. AC Immune expects to report the results of the study in Q3 2021. The clinical study is supported by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), building on The Foundation’s significant funding of AC Immune’s program since 2015.

Den gesamten Artikel lesen Sie bitte hier

News 2021

29.01.2021: AC Immune SA

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors

High-affinity antibodies against extracellular components of the inflammasome pathway show inhibition of target inflammatory responses

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced recent advancements in its small molecule- and antibody-based therapeutic programs targeting the (NOD)-like receptor protein 3 (NLRP3) inflammasome, a multi-protein complex that activates downstream inflammatory pathways leading to neuronal damage. The inflammasome is a highly valued therapeutic target implicated in a wide range of neurodegenerative disorders including Alzheimer’s disease (AD), as well as in non-central nervous system (CNS) indications, such as autoimmune and infectious diseases, as well as certain cancers.

Den gesamten Artikel lesen Sie bitte hier
News 2021
Older Entries
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • Unternehmen
    • AC Immune SA
    • Apogenix AG
    • Cassiopea SpA
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz